Safety and Immunogenicity of a Recombinant Parvovirus B19 Vaccine Formulated with MF59C.1

Citations Over TimeTop 10% of 2003 papers

Abstract

A recombinant human parvovirus B19 vaccine (MEDI-491; MedImmune) composed of the VP1 and VP2 capsid proteins and formulated with MF59C.1 adjuvant was evaluated in a randomized, double-blind, phase 1 trial. Parvovirus B19-seronegative adults (n=24) received either 2.5 or 25 microg MEDI-491 at 0, 1, and 6 months. MEDI-491 was safe and immunogenic. All volunteers developed neutralizing antibody titers that peaked after the third immunization and were sustained through study day 364.

Related Papers

• → Unusual skin manifestations associated with parvovirus B19 primary infection in children(2018)9 cited
• Variants of B19.(2004)
• → Parvovirus B19(2006)1 cited
• → Acute and chronic parvovirus infection(2021)
• → Parvovirus Vectors(2007)